Camille Fung, M.D. is an Associate Professor in the Division of Neonatology, Department of Pediatrics, at the University of Utah School of Medicine. In addition to caring for sick newborns in 3 level III & IV NICUs in the Salt Lake valley as a neonatologist, she has a basic science research interest in determining the effects of intrauterine growth restriction (IUGR) on hippocampal neuronal development. This is important because IUGR infants are at increased risk for cognitive delays particularly affecting learning and memory, functions that are performed by the hippocampus, but the underlying mechanisms leading to such delays remain elusive. Due to inaccessibility of fetal/neonatal brain tissue, she uses a mouse model of IUGR that she developed in 2010, which mimics human pregnancy-induced hypertension, to study embryonic and postnatal hippocampal neurogenesis and synaptic development. In addition to understanding IUGR's effects on the central nervous system (CNS), she has collaborations both within and outside of the University of Utah investigating the mechanisms of IUGR-induced retinopathy, necrotizing enterocolitis, and chronic lung disease/pulmonary hypertension. She has held a NIH-sponsored co-Investigator R01 grant on the last complication. Relating to her basic science interest on CNS function, she has quality improvement and clinical research interests on neonatal opioid withdrawal syndrome (NOWS). The incidence of NOWS has skyrocketed across the U.S., attributed to prescription opioid use and misuse. She has worked closely with interdisciplinary teams both at Intermountain and University Healthcare systems to implement a care process model on NOWS management. Working with the Utah Department of Health, she has also extended this care process model to other healthcare systems across Utah such that a standardized practice exists for infants suffering from NOWS. She is also a Principal Investigator and a co-Investigator on two NIH-funded clinical projects relating to NOWS. Lastly, recognizing the concurrent use of other substances along with prescription opioids, Dr. Fung has incepted a CME course to address the opioid epidemic since 2014 and has helped incept another course in 2020 to address the increasing use of cannabis in pregnant women. The first course satisfies the Utah Division of Professional Licensing (DOPL) requirement for opioid education mandated at each license cycle renewal and the second course satisfies the requirement to become a medical cannabis prescriber. These courses are accessible year round through the Substance Education Institute at substanceei.com. She has also mentored pediatric residents, neonatal-perinatal fellows, undergraduate and graduate students both in basic science and in clinical research.
American Board of Pediatrics (Sub: Neonatal-Perinatal Medicine)
Camille Fung, M.D. is an Associate Professor in the Division of Neonatology, Department of Pediatrics, at the University of Utah School of Medicine. In addition to caring for sick newborns in 3 level III & IV NICUs in the Salt Lake valley as a neonatologist, she has a basic science research interest in determining the effects of intrauterine growth restriction (IUGR) on hippocampal neuronal development. This is important because IUGR infants are at increased risk for cognitive delays particularly affecting learning and memory, functions that are performed by the hippocampus, but the underlying mechanisms leading to such delays remain elusive. Due to inaccessibility of fetal/neonatal brain tissue, she uses a mouse model of IUGR that she developed in 2010, which mimics human pregnancy-induced hypertension, to study embryonic and postnatal hippocampal neurogenesis and synaptic development. In addition to understanding IUGR's effects on the central nervous system (CNS), she has collaborations both within and outside of the University of Utah investigating the mechanisms of IUGR-induced retinopathy, necrotizing enterocolitis, and chronic lung disease/pulmonary hypertension. She has held a NIH-sponsored co-Investigator R01 grant on the last complication. Relating to her basic science interest on CNS function, she has quality improvement and clinical research interests on neonatal opioid withdrawal syndrome (NOWS). The incidence of NOWS has skyrocketed across the U.S., attributed to prescription opioid use and misuse. She has worked closely with interdisciplinary teams both at Intermountain and University Healthcare systems to implement a care process model on NOWS management. Working with the Utah Department of Health, she has also extended this care process model to other healthcare systems across Utah such that a standardized practice exists for infants suffering from NOWS. She is also a Principal Investigator and a co-Investigator on two NIH-funded clinical projects relating to NOWS. Lastly, recognizing the concurrent use of other substances along with prescription opioids, Dr. Fung has incepted a CME course to address the opioid epidemic since 2014 and has helped incept another course in 2020 to address the increasing use of cannabis in pregnant women. The first course satisfies the Utah Division of Professional Licensing (DOPL) requirement for opioid education mandated at each license cycle renewal and the second course satisfies the requirement to become a medical cannabis prescriber. These courses are accessible year round through the Substance Education Institute at substanceei.com. She has also mentored pediatric residents, neonatal-perinatal fellows, undergraduate and graduate students both in basic science and in clinical research.
